retatrutide clinical trial saudi arabia A new from Eli Lilly and Company suggests its experimental triple hormone drug, retatrutide, could become one of the next major medications in the rapidly growing weight loss and diabetes Retatrutide UK 2026: Phase 3

Disclaimer: This information is for general knowledge and informational purposes only and does not constitute medical advice

The science is finally catching up

For patients with persistent reflux symptoms despite 8 weeks of PPI therapy or those with alarm features, referral to gastroenterology for upper endoscopy may be warranted, consistent with American College of Gastroenterology guidelines

Key Takeaways Protein for GLP-1 weight loss is a lean-mass, appetite, and meal-structure strategy

However, in PCOS, reduced FSHR phosphorylation contributes to impaired follicular development and estrogen deficiency (59)

Appetite Control: By acting on the brains appetite centers, Semaglutide GLP-1 reduces feelings of hunger and promotes a sense of fullness, leading to decreased food intake